Percy W. C. Lomax

PERCY W. C. LOMAX has been Executive Chairman of ReGen Therapeutics Plc
since June 4, 1998. He was brought in to commercialize the intellectual
property of a Polish Institute. Mr. Lomax led the Ofex float in November
1998 and more importantly the flotation on AIM, which raised 5 million
in March 2000. His responsibilities, in addition to Chairing the Board,
have been corporate strategy, corporate governance, fundraising and
investor relations. During his time as Executive Chairman, the company
has been spending around 2.25 million each year. Mr. Lomax has been
responsible for recruitment, salary packages and the general overall
welfare of the staff. From January 11, 2001 to August 31, 2002 he was
Chairman at Mediwatch Plc. Mr. Lomax was brought in after the public
float at the request of the then brokers to steer the company through
its initial public period. This period has now expired. As a non-
Executive Chairman his duties were simply those commensurate with such a
post and did not include budgetary responsibility. He formed Lomax
Pharmaceutical Consulting in July 1998, to carry on the work started at
Teather & Greenwood. From August 2, 1995 to January 31, 1999, Mr. Lomax
was co-Founder and Director of Polymasc Pharmaceuticals Plc, developed
to commercialize the intellectual property of a department of the Royal
Free Hospital School of Medicine. This company was quoted on the AIM
market in December 1995, and in summer 1999 was taken over by Valentis
Incorporated. He was principally responsible for corporate governance,
fundraising and investor relations. From January 1, 1995 to June 30,
1998 he was Corporate Healthcare Broker for Teather & Greenwood. During
this time he was a leading person in the flotation of PolyMASC and
Oxford Biomedica and the rescue rights issue of Proteus. His experience
over the previous 10 years led him to believe he could do better on his
own. From January 1, 1992, to December 31, 1994, he joined Robert
Fleming Securities as Executive in charge of European pharmaceutical
research, and was appointed Manager in April 1993. The work involved
investment analysis and corporate broking. From January 6, 1990 to
December 31, 1991 he was working in European and UK Pharmaceutical Sales
and Research for Sheppards. His work involved all aspects of research
and selling. From January 4, 1989, to May 31, 1990, he was a European
Healthcare Analyst at Prudential Bache. From January 1987 to December
31, 1989, he was head of team researching and selling health care and
chemicals at T.C. Coombs. He was promoted to head of UK and European
Sales and Research. He was also in charge of a team of 10 with a budget
of around 0.5 million. During this time he floated Medirace, which
subsequently became Medeva in August 1987, now part of the largest UK
biotech company, Celltech. From October 1976 to September 1986 he was a
Pharmaceutical and Chemical Analyst for Vivian Gray & Co. and became a
general Partner and Head of Research. During this time he studied for
the Stock Exchange exams, which he passed. From November 1973 to October
1976 he joined the firm of Hart Morris as a Pharmaceutical and Chemical
Analyst directly from Fisons. From January 1970 to October 1973 he was a
Corporate Planning Executive for Fisons. From June 1967 to December 1969
he was Assistant to Commercial Intelligence Manager at Glaxo. This was
primarily a market research department. During his period there he
worked on the launch of Ventolin, at one time one of the 10 best selling
drugs in the world and still a very important medicine. Mr. Lomax has a
BSc Econ and is a Fellow of the Securities Institute.